Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin

Internal Medicine

Volumn 52, Issue 19, 2013, Pages 2179-2187

  Derosa, Giuseppe ^a   Carbone, Anna ^b   D'Angelo, Angela ^a   Querci, Fabrizio ^c   Fogari, Elena ^a   Cicero, Arrigo F G ^d   Maffioli, Pamela ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b Hospital Center of Diabetes   (Italy)

^c Ospedale Pesenti Fenaroli   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Metformin; Omentin 1; Sitagliptin; Tumor necrosis factor ; Vaspin

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; GLUCAGON; INFLAMMATORY BIOMARKER; INSULIN; METFORMIN; PLACEBO; PROINSULIN; RESISTIN; SITAGLIPTIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASPIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIET; EXERCISE; FEMALE; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INFLAMMATION MEDIATORS; MALE; METFORMIN; MIDDLE AGED; PYRAZINES; TRIAZOLES;

EID: 84884919313     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.52.8175     Document Type: Article

References (37)

1. Derosa G, Maffioli P. Dipeptidyl peptidase-4 inhibitors: 3 years of experience. Diabetes Technol Ther 14: 350-364, 2012.
2. Shirakawa J, Fujii H, Ohnuma K, et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 60: 1246-1257, 2011.
3. Koren S, Shemesh-Bar L, Tirosh A, et al. The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther 14: 561-567, 2012.
4. Derosa G, Maffioli P, Salvadeo SA, et al. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. Metabolism 59: 887-895, 2010.
5. Rydén L, Standl E, Bartnik M, et al; Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC), European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136, 2007.
6. Lichtenstein AH, Appel LJ, Brands M, et al. Summary of American Heart Association Diet and Lifestyle Recommendations Revision 2006. Arterioscler Thromb Vasc Biol 26: 2186-2191, 2006.
7. Bunn HF, Gabbay KH, Gallop PM. The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 200: 21-27, 1978.
8. European Diabetes, Policy Group. A desktop guide to type 2 diabetes mellitus. Diabet Med 16: 716-730, 1999.
9. Heding LG. Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 8: 260-266, 1972.
10. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985.
11. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 27: 1487-1495, 2004.
12. Houssa P, Dinensen B, Deberg M, et al. First direct assay for intact human proinsulin. Clin Chem 44: 1514-1519, 1998.
13. El Kenz H, Bergmann P. Evaluation of immunochemiluminometric assays for the measurement of insulin and C-peptide using the ADVIA Centaur. Clinical Laboratory 50: 171-174, 2004.
14. Holst JJ. Evidence that peak II GLI or enteroglucagon is identical to the C-terminal sequence (residues 33-69) of glicentin. Biochem J 207: 381-388, 1982.
15. Yannakoulia M, Yiannakouris N, Blüher S, Matalas AL, Klimis-Zacas D, Mantzoros CS. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 88: 1730-1736, 2003.
16. Hida K, Wada J, Eguchi J, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocy-tokine in obesity. Proc Natl Acad Sci U S A 102: 10610-10615, 2005.
17. De Souza Batista CM, Yang RZ, Lee MJ, et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 56: 1655-1661, 2007.
18. Zhang M, Tracey K. The Cytokine Handbook. 3rd ed. Academic Press, San Diego, USA, 1988.
19. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-E223, 1979.
20. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 32: 762-768, 2009.
21. Fasching P, Ratheiser K, Nowotny P, Uurzemann S, Parker S, Waldhaus W. Insulin production following intravenous glucose, ar-ginine, and valine: different pattern in patients with impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metabolism 43: 385-389, 1994.
22. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. McGraw-Hill, New York, 1971.
23. Derosa G, Carbone A, Franzetti I, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glyce-mic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract 98: 51-60, 2012.
24. Azuma K, Oguchi S, Matsubara Y, et al. Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 36: 564-570, 2004.
25. Bouchard L, Weisnagel SJ, Engert JC, et al. Human resistin gene polymorphism is associated with visceral obesity and fasting and oral glucose stimulated C-peptide in the Québec Family Study. J Endocrinol Invest 27: 1003-1009, 2004.
26. McTernan PG, Fisher FM, Valsamakis G, et al. Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosigli-tazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88: 6098-6106, 2003.
27. Ohmori R, Momiyama Y, Kato R, et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 46: 379-380, 2005.
28. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. Prog Biophys Mol Biol 107: 248-256, 2011.
29. Kim SJ, Nian C, McIntosh CH. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 282: 34139-34147, 2007.
30. Youn BS, Klöting N, Kratzsch J, et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 57: 372-377, 2008.
31. El-Mesallamy HO, Kassem DH, El-Demerdash E, Amin AI. Vaspin and visfatin/Nampt are interesting interrelated adipokines playing a role in the pathogenesis of type 2 diabetes mellitus. Metabolism 60: 63-70, 2011.
32. Yang RZ, Lee MJ, Hu H, et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab 290: E1253-E1261, 2006.
33. Schäffler A, Neumeier M, Herfarth H, Fürst A, Schölmerich J, Büchler C. Genomic structure of human omentin, a new adipocy-tokine expressed in omental adipose tissue. Biochim Biophys Acta 1732: 96-102, 2005.
34. Kralisch S, Klein J, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Therapeutic perspectives of adipocytokines. Expert Opin Phar-macother 6: 863-872, 2005.
35. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389: 610-614, 1997.
36. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259: 87-91, 1993.
37. Hotamisligil GS. The role of TNF-alpha and TNF receptors in obesity and insulin resistance. J Intern Med 245: 621-625, 1999.